Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Sildenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms SUPERIOR
- 11 Jul 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 29 Dec 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018 as per ClinicalTrials.gov record.
- 29 Dec 2015 Planned primary completion date changed from 1 May 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.